A role for genetically engineered phages in personalised medicine?
In May 2019, Great Ormond Street Hospital (GOSH) made headline news with a report of pioneering bacteriophage therapy in the treatment of a 15-year-old cystic fibrosis (CF) patient with a life-threatening Mycobacterium abscessus infection.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.